CDR grafted humanised chimeric T-cell antibodies
US5502167A · kind A · utility
134Cited by
0References
6Claims
0Family size
Inventors
Key dates
| Filing date | Jul 15, 1994 |
| Grant date | Mar 26, 1996 |
| Priority date | — |
| Expiry date | Jul 15, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A humanised antibody is provided in which the amino acid sequence of the CDRs is derived from the sequence of CDRs of a monoclonal antibody having the specificity of binding to resting and activated T-cells, inhibiting T-cell proliferation and lysing T-cells from mice transgenic for human CD2 and in which sufficient of the amino acid sequence of each CDR has been retained to provide the same specificity for the humanised antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.